MindMed Launches Psychedelic-Based Pain Treatment Project

Mind Medicine Inc. (NEO: MMED), also known as MindMed, announced today that it has launched Project Angie. The project is the company’s effort to advance psychedelics, including LSD, as a means of pain treatment.

The company is currently exploring two primary clinical indications for the treatment of pain. First, MindMed will initiate a study of LSD in a severe pain indication. It is in the process of preparing for a proof of concept study which it intends to submit to the US FDA in the second half of 2021.

MindMed is also evaluating a second indication in a common, often debilitating, chronic pain syndrome.

According to IQVIA, the global market for analgesics is expected to grow over US$31 billion by 2030. MindMed CEO J.R. Rahn relayed that Project Angie is related to the company’s mission to improve mental health and combat substance use. “If we can help to develop a new paradigm to treat pain, it may have the potential to greatly reduce the use of addictive medicines such as opioids currently ravaging society and its mental health,” said Rahn.

Earlier this year, MindMed also launched a clinical trial to combine LSD and MDMA, and began the study on LSD neutralizer technology that aims to stop the substance’s trip effects during therapy.

Mind Medicine Inc. last traded at US$3.38 on the Nasdaq.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Goliath Resources Hits 10.60 g/t Gold Over 22.82 Metres, Highest Grade Results In Third Distinct Rock Package At Surebet Discovery

Four Countries Control the Fertilizer That Feeds the World | Sage Potash

$10,000 Gold Is Just A Question of Time | Florian Grummes

Recommended

ESGold Outlines $24.3 Million NPV For Tailings Reprocessing Project

First Majestic Encounters 711 g/t Silver Equivalent Over 8.0 Metres In Ongoing Exploration At Los Gatos

Related News

MindMed Presents Positive Data Studying LSD In Treating Anxiety Disorders

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced today that its top...

Wednesday, May 11, 2022, 10:27:55 AM

MindMed To Begin Trading On The Nasdaq April 27

MindMed (NEO: MMED) is moving up to the big leagues. The psychedelics company this morning...

Friday, April 23, 2021, 09:11:58 AM

MindMed Closes $34.5 Million Financing, Cash Reserves Said To Be At $85 Million

Mind Medicine (NEO: MMED) has completed its previously announced bought deal private placement, raising gross...

Friday, December 11, 2020, 09:15:15 AM

Mindmed: Eight Capital Resumes Coverage With $6.50 Price Target

Earlier this week, Eight Capital launched coverage on a basket of psychedelic companies. This comes...

Friday, September 17, 2021, 03:23:00 PM

20-Year-Old Makes $110 Million From Bed Bath & Beyond Stock.. Next Stop: MindMed

20-year-old Jake Freeman just walked away with around $110 million from selling his 6.21% stake...

Thursday, August 18, 2022, 09:26:36 AM